BRPI0815360A2 - Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto - Google Patents

Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto

Info

Publication number
BRPI0815360A2
BRPI0815360A2 BRPI0815360-4A2A BRPI0815360A BRPI0815360A2 BR PI0815360 A2 BRPI0815360 A2 BR PI0815360A2 BR PI0815360 A BRPI0815360 A BR PI0815360A BR PI0815360 A2 BRPI0815360 A2 BR PI0815360A2
Authority
BR
Brazil
Prior art keywords
pyrimidinosulfamide
pharmaceutical composition
composition containing
derivative compound
pair preparation
Prior art date
Application number
BRPI0815360-4A2A
Other languages
English (en)
Inventor
Martin Bolli
Christoph Boss
Alexander Treiber
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815360(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0815360A2 publication Critical patent/BRPI0815360A2/pt
Publication of BRPI0815360A8 publication Critical patent/BRPI0815360A8/pt
Publication of BRPI0815360B1 publication Critical patent/BRPI0815360B1/pt
Publication of BRPI0815360B8 publication Critical patent/BRPI0815360B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
BRPI0815360A 2007-08-17 2008-08-15 composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto BRPI0815360B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007053292 2007-08-17
IB2008052571 2008-06-26
PCT/IB2008/053282 WO2009024906A1 (en) 2007-08-17 2008-08-15 4-pyrimidinesulfamide derivative

Publications (4)

Publication Number Publication Date
BRPI0815360A2 true BRPI0815360A2 (pt) 2015-02-10
BRPI0815360A8 BRPI0815360A8 (pt) 2017-12-26
BRPI0815360B1 BRPI0815360B1 (pt) 2018-12-04
BRPI0815360B8 BRPI0815360B8 (pt) 2021-05-25

Family

ID=40140023

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815360A BRPI0815360B8 (pt) 2007-08-17 2008-08-15 composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto

Country Status (31)

Country Link
US (1) US8324232B2 (pt)
EP (1) EP2190837B1 (pt)
JP (1) JP5323075B2 (pt)
KR (1) KR101528946B1 (pt)
CN (1) CN101772494B (pt)
AR (1) AR070018A1 (pt)
AU (1) AU2008290234B2 (pt)
BR (1) BRPI0815360B8 (pt)
CA (1) CA2695511C (pt)
CY (2) CY1113255T1 (pt)
DK (1) DK2190837T3 (pt)
ES (1) ES2394584T3 (pt)
FI (1) FIC20240041I1 (pt)
FR (1) FR24C1047I2 (pt)
HR (1) HRP20120878T1 (pt)
HU (1) HUS2400041I1 (pt)
IL (1) IL203936A (pt)
LT (1) LTPA2024534I1 (pt)
MA (1) MA31702B1 (pt)
MX (1) MX2010001837A (pt)
MY (1) MY152281A (pt)
NL (1) NL301304I2 (pt)
NO (1) NO2024053I1 (pt)
NZ (1) NZ583990A (pt)
PL (1) PL2190837T3 (pt)
PT (1) PT2190837E (pt)
RU (1) RU2485116C2 (pt)
SI (1) SI2190837T1 (pt)
TW (1) TWI411437B (pt)
WO (1) WO2009024906A1 (pt)
ZA (1) ZA201001872B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
WO2017093903A1 (en) * 2015-11-30 2017-06-08 Laurus Labs Private Limited An improved process for the preparation of macitentan
WO2017191565A1 (en) * 2016-05-04 2017-11-09 Shilpa Medicare Limited Process for preparation of macitentan
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
KR20260037123A (ko) * 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
CN108997223B (zh) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 5-(4-溴苯基)-4,6-二氯嘧啶的制备方法
CA3123990A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020378025A1 (en) * 2019-11-07 2022-06-23 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2021237004A1 (en) 2020-05-21 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技(台州)有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
AU2023276826A1 (en) 2022-05-22 2025-01-09 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
US20250340520A1 (en) 2022-05-25 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
CN119330888B (zh) * 2024-10-25 2025-11-28 上海药坦药物研究开发有限公司 一种阿普昔腾坦的制备方法
CN119528820B (zh) * 2024-11-29 2025-10-10 浙江国邦药业有限公司 一种阿普昔腾坦的合成方法
CN119528821B (zh) * 2024-11-29 2025-10-10 浙江国邦药业有限公司 一种阿普昔腾坦的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5523204A (en) 1993-12-10 1996-06-04 Becton Dickinson And Company Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (pt) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997022595A1 (en) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
DE60037308T2 (de) 1999-09-03 2008-10-30 Actelion Pharmaceuticals Ltd. Bis-sulfonamiden
CN1407973A (zh) 1999-12-22 2003-04-02 埃科特莱茵药品有限公司 丁炔二醇衍生物
US20040062803A1 (en) 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
HUP0203935A3 (en) 1999-12-31 2006-02-28 Encysive Pharmaceuticals Inc H Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ ファーマシューティカル インダストリーズ リミティド カルベジロール
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
HU229403B1 (en) * 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
KR20100090726A (ko) 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
JP4769460B2 (ja) * 2002-12-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド 新規スルファミド類
HRP20050675A2 (en) 2003-02-25 2005-10-31 Eli Lilly And Company Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano

Also Published As

Publication number Publication date
SI2190837T1 (sl) 2012-11-30
DK2190837T3 (da) 2012-10-08
CY1113255T1 (el) 2016-04-13
HUS2400041I1 (hu) 2024-12-28
RU2010109543A (ru) 2011-09-27
PL2190837T3 (pl) 2013-01-31
BRPI0815360A8 (pt) 2017-12-26
JP2010536742A (ja) 2010-12-02
MX2010001837A (es) 2010-03-10
PT2190837E (pt) 2012-10-31
FR24C1047I2 (fr) 2025-10-10
KR101528946B1 (ko) 2015-06-15
CY2024031I1 (el) 2026-02-25
BRPI0815360B8 (pt) 2021-05-25
AR070018A1 (es) 2010-03-10
FIC20240041I1 (fi) 2024-12-02
KR20100052517A (ko) 2010-05-19
CN101772494B (zh) 2013-05-15
ZA201001872B (en) 2011-05-25
AU2008290234B2 (en) 2013-11-21
LTPA2024534I1 (pt) 2024-12-27
TW200927122A (en) 2009-07-01
NZ583990A (en) 2012-06-29
NO2024053I1 (no) 2024-12-03
FR24C1047I1 (fr) 2025-01-10
JP5323075B2 (ja) 2013-10-23
CN101772494A (zh) 2010-07-07
CA2695511C (en) 2015-11-03
TWI411437B (zh) 2013-10-11
MY152281A (en) 2014-09-15
NL301304I2 (nl) 2024-12-19
BRPI0815360B1 (pt) 2018-12-04
US20120142716A1 (en) 2012-06-07
CA2695511A1 (en) 2009-02-26
WO2009024906A1 (en) 2009-02-26
ES2394584T3 (es) 2013-02-04
IL203936A (en) 2016-03-31
CY2024031I2 (el) 2026-02-25
MA31702B1 (fr) 2010-09-01
AU2008290234A1 (en) 2009-02-26
US8324232B2 (en) 2012-12-04
HRP20120878T1 (hr) 2012-11-30
EP2190837B1 (en) 2012-08-15
EP2190837A1 (en) 2010-06-02
RU2485116C2 (ru) 2013-06-20
HK1144196A1 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
BRPI0815360A2 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0821004A2 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0617159A2 (pt) COMPOSTOS DE PIRIDOPIRIMIDINONE INIBIDORES DE PI3Ka, COMPOSIÇÕES QUE OS CONTEM E PROCESSO PARA PREPARO
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0822946A2 (pt) Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0815405A2 (pt) Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
BRPI0814308A2 (pt) Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0820673A2 (pt) Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF